← All trials
NCT04761601
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 3, 2021
- Primary completion
- Sep 23, 2023
- Completion date
- Aug 1, 2024
- First posted
- Feb 21, 2021
- Last posted
- Mar 30, 2021
- Enrollment
- 106
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- 1200 Pharma, LLCLead sponsor
- 1200 Pharma, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.